{"id":"NCT00269399","sponsor":"Bausch Health Americas, Inc.","briefTitle":"A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)","officialTitle":"A Double-Blind, Randomized, Controlled Trial of Rifaximin Compared to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-12","primaryCompletion":"2008-12","completion":"2008-12","firstPosted":"2005-12-23","resultsPosted":"2019-10-01","lastUpdate":"2019-10-14"},"enrollment":237,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Clostridium Infections","Diarrhea"],"interventions":[{"type":"DRUG","name":"Rifaximin (Xifaxan)","otherNames":[]},{"type":"DRUG","name":"Vancomycin","otherNames":[]}],"arms":[{"label":"Rifaximin Treatment Arm","type":"EXPERIMENTAL"},{"label":"Vancomycin Comparator Arm","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to assess the treatment and safety of a 10-day course of rifaximin (Xifaxan) as compared to vancomycin for treatment of Clostridium difficile-associated diarrhea (CDAD).","primaryOutcome":{"measure":"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea.","timeFrame":"14 days","effectByArm":[{"arm":"Rifaximin Treatment Arm","deltaMin":67,"sd":null},{"arm":"Vancomycin Comparator Arm","deltaMin":73,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":63,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":28,"n":120},"commonTop":["Insomnia"]}}